RankingsPricing
  1. US-listed companies
  2. Citius Pharmaceuticals, Inc.
  3. Raw

Citius Pharmaceuticals, Inc.CTXR

Market cap
$10.7M
P/E ratio
SummaryFinancials
Back to summarized table
Sep 30,
2011		Sep 30,
2012		Sep 30,
2013		Sep 30,
2015		Sep 30,
2016		Sep 30,
2017		Sep 30,
2018		Sep 30,
2019		Sep 30,
2020		Sep 30,
2021		Sep 30,
2022		Sep 30,
2023		Sep 30,
2024
Net Loss-------------39,425,839
Stock-based compensation – general and administrative---486,271732,151986,620779,701715,983803,26114712
Issuance of common stock for services-----------102,000284,176
Amortization of operating lease right-of-use asset----------176,754191,648208,179
Depreciation----1,3432,6321,7538938441,4922,9232,6681,432
Deferred income tax expense----------576,000576,000576,000
Inventory------------2
Prepaid expenses----60,000-40,759-572,098-162,514-9,62174,1263111,1765945,389
Accounts payable906-11,474452,981105,230-306,725971,0131-857,307-579,140-111,71722
Accrued expenses3,9504,1502,700-52,057351,182-397,18370,73964,568-82,185457,920783,434-929,094-459,273
Accrued compensation------------72,035
Operating lease liability---------123,254-158,999-177,237-196,989-218,380
Net Cash Used In Operating Activities-20,781-20,324-20,604-2,385,416-5,900,421-7,971,205-11,318,138-12,437,751-16,930,658-24,250,414-28,361,256-29,060,212-28,201,375
License payment------------5
Net Cash Used In Investing Activities----255,748-2,126---1,831-40,006,938---5,000,000
Proceeds from common stock option exercises-----40-----31,267-
Merger, net------------4
Net proceeds from registered direct offerings-----6---71-1414
Net Cash Provided By Financing Activities36,49356,74077,2092511171123120-1410
Net Change in Cash and Cash Equivalents--------656-28,361,256-15,230,762-23,229,048
IPR&D Milestones included in License Payable------------28
Prepaid Manufacturing transferred to Inventory------------6